← Evidence library

BIB_167

Blank CU et al. Neoadjuvant nivolumab + ipilimumab vs adjuvant nivolumab in macroscopic stage III melanoma (NADINA). NEJM 2024;391(18):1696–1708. PMID 38875268. n=423; EFS HR 0.32 (68% reduction); pCR ~58%. Practice-changing — neoadjuvant ipi+nivo now standard at Stage III. [Tasks: 17, 18] Tier: 1 Grade: A Retrieved: 2026-05-07

Evidence grade

A

Tier

1

Cited by tasks

17, 18

Identifiers

PMID:38875268

↗ Follow the original source for full context

Full extracted findings & patient-implication analysis: bibliography/BIB_167/findings.md (research corpus). This page is a short context summary — not individualised medical advice.